18F-LNC1007

N/A

Report date: 2025/11/27 20:00:08
NME

Base Information

Drug Name18F-LNC1007
Drug Alias Name18F-LNC100718F-FAPI-RGD
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionPositron-emission tomography enhancersIntegrin alpha-V/beta-3 modulatorsFibroblast activation protein alpha modulators
TargetsIntegrin alpha-V/beta-3Prolyl endopeptidase FAP
Therapy Area/IndicationsDiagnostic agentsSolid tumoursCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesYantai Lannacheng Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesYantai Lannacheng Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiagnostic agentsSolid tumoursCarcinoma, Renal Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A